Status:
COMPLETED
Vinorelbine for Recurrent ACLC
Lead Sponsor:
Children's Cancer Group, China
Conditions:
Anaplastic Large Cell Lymphoma
Vinorelbine
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the efficiency and safety of vinorelbine in the treatment of relapsed / advanced ALCL in children and adolescents.
Detailed Description
Anaplastic large cell lymphoma (ALCL) is a rare non-Hodgkin's lymphoma, around 30% patients would get relapse. Vinorelbine(Navelbine) is a third-line treatment option for Hodgkin's disease(HD) after t...
Eligibility Criteria
Inclusion
- Children and adolescents with a clear diagnosis of recurrent / progressive ALCL at Shanghai Children's Medical Center or other centers since September 2017 include:
- Diagnosed as ALCL, already received first-line treatment, but get disease progression;
- After receiving ALCL treatment has got CR then diagnosed relapse, need for pathological diagnosis.
Exclusion
- Patients with other systemic diseases, severe infections or critically illness.
Key Trial Info
Start Date :
November 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03397953
Start Date
November 1 2016
End Date
July 1 2022
Last Update
July 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Children's Medical Center
Shanghai, Shanghai Municipality, China, 200127